US Patent
US11576894 — Combination therapy for the treatment of diabetes
Formulation · Assigned to Janssen Pharmaceutica NV · Expires 2030-07-06 · 4y remaining
Vulnerability score
56/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a combination therapy for treating and preventing glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.
USPTO Abstract
The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.
Drugs covered by this patent
- Invokana (CANAGLIFLOZIN) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.